Abstract
Since Bortezomib was approved by US FDA as the first drug to treat multiple myeloma, various boronic acid compounds have been developed as enzyme inhibitors. This paper reviewed the progress of boronic acid-based inhibitors against enzymes including proteasome, serine protease, HDACs and other enzymes in the past decade.
Keywords: Boronic acid, bortezomib, enzyme inhibitor, HDACs, proteasome inhibitor, serine protease.
Current Medicinal Chemistry
Title:Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress
Volume: 21 Issue: 28
Author(s): H. Fu, H. Fang, Jie Sun, H. Wang, A. Liu, J. Sun and Z. Wu
Affiliation:
Keywords: Boronic acid, bortezomib, enzyme inhibitor, HDACs, proteasome inhibitor, serine protease.
Abstract: Since Bortezomib was approved by US FDA as the first drug to treat multiple myeloma, various boronic acid compounds have been developed as enzyme inhibitors. This paper reviewed the progress of boronic acid-based inhibitors against enzymes including proteasome, serine protease, HDACs and other enzymes in the past decade.
Export Options
About this article
Cite this article as:
Fu H., Fang H., Sun Jie, Wang H., Liu A., Sun J. and Wu Z., Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress, Current Medicinal Chemistry 2014; 21 (28) . https://dx.doi.org/10.2174/0929867321666140601200803
DOI https://dx.doi.org/10.2174/0929867321666140601200803 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lung Cancer: Are we up to the Challenge?
Current Genomics EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design STING Activation and its Application in Immuno-Oncology
Current Topics in Medicinal Chemistry New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Vaccines Explored in Patients with Non-Small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting CREB for Cancer Therapy: Friend or Foe
Current Cancer Drug Targets Molecular Targets in Malignant Pleural Mesothelioma Treatment
Current Drug Targets Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy
Current Drug Safety Multi-modal Anti-cancer Activities Provided by a Non-replicating Sendai Virus Envelope
Current Cancer Therapy Reviews Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design Use of Anti-Cancer Drugs, Mitocans, to Enhance the Immune Responses against Tumors
Current Pharmaceutical Biotechnology Epigenetic Alterations of the Wnt/β -Catenin Pathway in Human Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells
Current Cancer Drug Targets Impaired Expression and Function of Cancer-Related Enzymes by Anthocyans: An Update
Current Enzyme Inhibition Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Disruption of Metabolic Pathways - Perspectives for the Treatment of Cancer
Current Cancer Drug Targets The Management of Thymoma - A Review of the Status Quo with Practical Treatment Recommendations
Current Respiratory Medicine Reviews Proton Ion-Microbeam Elemental Analysis for Inhaled Particle-Induced Pulmonary Diseases: Application for Diagnosis and Assessment of Progression
Current Medicinal Chemistry